DGAP-PVR: Epigenomics AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


Epigenomics AG 

04.09.2015 21:40

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------


Voting Rights: Release of Voting Rights Notifications (§ 21 para. 1 WpHG)
in Accordance with § 26 para. 1 WpHG (German Securities Trading Act) with
the Aim of an Europe-wide Distribution

Issuer:

Epigenomics AG
- ISIN DE000A11QW50 -
Geneststr. 5
10829 Berlin
Deutschland

Voting Rights Notifications:

 1. On 4 September 2015, the company Morgan Stanley, Wilmington, Delaware,
    USA, notified Epigenomics AG of voting rights in Epigenomics AG
    pursuant to sec. 21 para. 1 WpHG as follows:

On 31 August 2015, as a consequence of the acquisition of shares to which
voting rights are attached, the share of Morgan Stanley in the voting
rights of Epigenomics AG exceeded the 3 per cent threshold of sec. 21 para.
1 WpHG and amounted, as at this date, to 4.83 per cent of the voting rights
(864,419 voting rights) in Epigenomics AG.

All 4.83 per cent of the voting rights (864,419 voting rights) are
attributed to Morgan Stanley pursuant to sec. 22 para. 1 sent. 1 no. 1 WpHG
through the following entities controlled by Morgan Stanley and holding 3
per cent or more of the voting rights in Epigenomics AG:

  - Morgan Stanley Capital Management, LLC

  - Morgan Stanley Domestic Holdings, Inc.

  - Morgan Stanley & Co. LLC

 2. Furthermore, on 4 September 2015, Morgan Stanley Capital Management,
    LLC, Wilmington, Delaware, USA, notified Epigenomics AG of voting
    rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG as follows:

On 31 August 2015, as a consequence of the acquisition of shares to which
voting rights are attached, the share of Morgan Stanley Capital Management,
LLC in the voting rights of Epigenomics AG exceeded the 3 per cent
threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.83
per cent of the voting rights (864,419 voting rights) in Epigenomics AG.

All 4.83 per cent of the voting rights (864,419 voting rights) are
attributed to Morgan Stanley Capital Management, LLC pursuant to sec. 22
para. 1 sent. 1 no. 1 WpHG through the following entities controlled by
Morgan Stanley Capital Management, LLC and holding 3 per cent or more of
the voting rights in Epigenomics AG:

  - Morgan Stanley Domestic Holdings, Inc.

  - Morgan Stanley & Co. LLC

  3. Furthermore, on 4 September 2015, Morgan Stanley Domestic Holdings,
    Inc., Wilmington, Delaware, USA, notified Epigenomics AG of voting
    rights in Epigenomics AG pursuant to sec. 21 para. 1 WpHG as follows:

On 31 August 2015, as a consequence of the acquisition of shares to which
voting rights are attached, the share of Morgan Stanley Domestic Holdings,
Inc. in the voting rights of Epigenomics AG exceeded the 3 per cent
threshold of sec. 21 para. 1 WpHG and amounted, as at this date, to 4.83
per cent of the voting rights (864,419 voting rights) in Epigenomics AG.

All 4.83 per cent of the voting rights (864,419 voting rights) are
attributed to Morgan Stanley Domestic Holdings, Inc. pursuant to sec. 22
para. 1 sent. 1 no. 1 WpHG through the following entity controlled by
Morgan Stanley Domestic Holdings, Inc. and holding 3 per cent or more of
the voting rights in Epigenomics AG:

  - Morgan Stanley & Co. LLC

  4. Furthermore, on 4 September 2015, Morgan Stanley & Co. LLC,
Wilmington,
    Delaware, USA, notified Epigenomics AG of voting rights in Epigenomics
    AG pursuant to sec. 21 para. 1 WpHG as follows:

On 31 August 2015, as a consequence of the acquisition of shares to which
voting rights are attached, the share of Morgan Stanley & Co. LLC in the
voting rights of Epigenomics AG exceeded the 3 per cent threshold of sec.
21 para. 1 WpHG and amounted, as at this date, to 4.83 per cent of the
voting rights (864,419 voting rights) in Epigenomics AG.

Date of release: 4 September 2015

Epigenomics AG 
The Executive Board

Contact: 

Epigenomics AG
Antje Zeise
Manager Investor Relations
Tel.: +49 (0)30 24345 386
Fax: +49 (0)30 24345 555
Email: antje.zeise@epigenomics.com



04.09.2015 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Epigenomics AG
              Geneststraße 5
              10829 Berlin
              Germany
Internet:     www.epigenomics.com
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------